NCT02240459 - A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions

Overactive BladderMild Cognitive Impairment

Interventions

DRUG

fesoterodine 4mg

7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

DRUG

Oxybutynin

5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

DRUG

placebo

placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

DRUG

fesoterodine 8mg

2, 4mg fesoterodine capsules taken together in the morning

Trial Locations (1)

Division of Geriatric Medicine, Clinical Sciences Building, University of Alberta Hosp, Edmonton